Appili Therapeutics announced that the National Institute of Allergy and Infectious Diseases (NIAID) has terminated its contract for the development of the VXV-01 fungal vaccine program. The contract, awarded in October 2025 with a base period of 22 months and funding of US$3.6 million, was ended for convenience. Despite this setback, Appili is focusing on advancing ATI-1801, a late-stage drug candidate for cutaneous leishmaniasis, which holds potential for near-term value and Priority Review Voucher monetization. The company continues to seek non-dilutive funding and strategic collaborations to support its infectious disease pipeline and maintain sustainable revenue through its commercial product LIKMEZ® royalties.
The Québec Superior Court has approved a restructuring transaction for Premier Health of America Inc., allowing the company to continue uninterrupted operations. The deal involves the acquisition of three affiliates by Polar Valley Investments Limite...
Alvotech announced that Celtic Lux Holdings S.a. r.l., formerly Alvogen Lux Holdings, pledged 88,940,619 shares and 7,007,321 Swedish warrants equivalent to shares on June 26. This transaction was reported to Luxembourg's financial regulator CSSF. Th...
Canada's federal government and British Columbia have signed the Cooperative Prosperity Agreement, aiming to unlock over $200 billion in new investments focused on natural resources like LNG, critical minerals, and infrastructure. Concurrently, Alber...
Crédit Agricole has increased its ownership in Banco BPM to 29.3%, surpassing the 25% threshold through market purchases and derivatives. This move reflects Crédit Agricole's commitment as a long-term investor supporting the Italian economy and stren...
Fartcoin surged 21% after its holder count hit a new record with about 80 new wallets added, driven mainly by retail investors. The rally was supported by strong buying volume on 15 of 19 exchanges, especially Binance, and positive funding rates indi...
